Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat

被引:21
作者
Erman, A
Veksler, S
Gafter, U
Boner, G
Wittenberg, C
van Dijk, D
机构
[1] Rabin Med Ctr, Dept Hypertens & Nephrol, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
renin-angiotensin system; TGF ACE-beta 1; ARB; diabetes mellitus; proteinuria;
D O I
10.3317/jraas.2004.032
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Introduction Combination therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is used to improve renal outcome achieved by monotherapy in diabetic patients. In addition, interference with the renin-angiotensin system (RAS) reduced expression and excretion of transforming growth factor beta(1) (TGF-beta(1)) in diabetic nephropathy. The aim of this study was to investigate the effects of interrupting the RAS by ACE inhibitor (ACE-I) or ARB monotherapy or by combination therapy on proteinuria, kidney hypertrophy and plasma TGF-beta(1) in diabetic rats. Materials and methods Forty-one male Wistar rats were allocated to five groups: 1 = control rats, 2 = diabetic rats (streptozotocin [STZ] 55 mg/kg), 3 = diabetic rats as above receiving enalapril (20 mg/kg/day), 4 = diabetic rats receiving losartan (80 mg/kg/day), 5 = diabetic rats receiving both losartan and enalapril. The study lasted 60 days. Results Urinary protein excretion, kidney weight, serum ACE activity and plasma TGF-beta(1) increased significantly in untreated diabetic rats compared with controls. Administration of losartan, enalapril, or both for 60 days prevented these changes. Furthermore, combined therapy for 30 days normalised urinary protein excretion, while monotherapy did not. Losartan inhibited serum ACE activity both in vivo and in vitro. Plasma TGF-beta(1) levels were positively correlated with blood glucose levels (r=0.4059) and with urinary protein excretion (r=0.3558). Conclusions Combination therapy with losartan and enalapril was more effective than monotherapy with either drug in achieving an early antiproteinuric response. Long-term treatment with losartan was as effective as the combined treatment, possibly due to a dual inhibitory effect on the RAS. The antiproteinuric effect may be related, in part, to reduced TGF-beta(1).
引用
收藏
页码:146 / 151
页数:6
相关论文
共 36 条
[1]   Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels [J].
Agarwal, R ;
Siva, S ;
Dunn, SR ;
Sharma, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :486-492
[2]  
Agarwal R, 2001, KIDNEY INT, V59, P2282, DOI 10.1046/j.1523-1755.2001.0590062282.x
[3]   Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy [J].
Andersen, S ;
Tarnow, L ;
Rossing, P ;
Hansen, BV ;
Parving, HH .
KIDNEY INTERNATIONAL, 2000, 57 (02) :601-606
[4]   RENAL RENIN-ANGIOTENSIN SYSTEM IN DIABETES - FUNCTIONAL, IMMUNOHISTOCHEMICAL, AND MOLECULAR BIOLOGICAL CORRELATIONS [J].
ANDERSON, S ;
JUNG, FF ;
INGELFINGER, JR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04) :F477-F486
[5]   Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat [J].
Benigni, A ;
Zoja, C ;
Corna, D ;
Zatelli, C ;
Conti, S ;
Campana, M ;
Gagliardini, E ;
Rottoli, D ;
Zanchi, C ;
Abbate, M ;
Ledbetter, S ;
Remuzzi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1816-1824
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   COMPARISONS INVITRO, EXVIVO, AND INVIVO OF THE ACTIONS OF 7 STRUCTURALLY DIVERSE INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME (ACE) [J].
CUSHMAN, DW ;
WANG, FL ;
FUNG, WC ;
GROVER, GJ ;
HARVEY, CM ;
SCALESE, RJ ;
MITCH, SL ;
DEFORREST, JM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 :S115-S131
[9]   INHIBITION OF ANGIOTENSIN CONVERTING ENZYME BY RAMIPRIL IN SERUM AND TISSUE OF MAN [J].
ERMAN, A ;
WINKLER, J ;
CHENGAL, B ;
RABINOV, M ;
ZELYKOVSKI, A ;
TADJER, S ;
SHMUELI, J ;
LEVI, E ;
AKBARY, A ;
ROSENFELD, JB .
JOURNAL OF HYPERTENSION, 1991, 9 (11) :1057-1062
[10]   ANGIOTENSIN-CONVERTING ENZYME-ACTIVITY IN THE SERUM, LUNG AND KIDNEY OF DIABETIC RATS [J].
ERMAN, A ;
VANDYK, DJ ;
CHENGAL, B ;
GILER, IDS ;
ROSENFELD, JB ;
BONER, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (10) :615-620